HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CARDURA safely and effectively. See full prescribing information for CARDURA.
CARDURA® (doxazosin mesylate) tablets, for oral use
Initial U.S. Approval: 1990
INDICATIONS AND USAGE
CARDURA is an alpha1 adrenergic antagonist indicated for: (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
WARNINGS AND PRECAUTIONS
The most commonly reported adverse reactions from clinical trials are Fatigue, malaise, hypotension, and dizziness. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
CARDURA® (doxazosin mesylate tablets) Highlights
No Current Announcements.
Report an Adverse Event